文献速递肿瘤 PET/CT

68Ga-PSMA PET/CT肿瘤强度术前预测局限性前列腺癌的不良病理结局和无进展生存期

68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-07-22

本研究为71例经MRI引导活检证实前列腺癌并接受根治性前列腺切除术患者的队列研究,术前68Ga-PSMA-11 PET/CT的腺内PSMA强度可预测Gleason评分、活检升级、病理分期、切缘阳性及生化无进展生存期;在活检Gleason评分≤3+4患者中,高PSMA强度(SUVmax>8)较低强度(SUVmax<8)的进展风险增加5.48倍。

要点

  • 术前68Ga-PSMA-11 PET/CT腺内强度可预测根治性前列腺切除术后不良病理结局和生化无进展生存期。
  • 活检Gleason评分≤3+4患者中,PSMA强度是無进展生存期最显著预测因子,高SUVmax>8较低SUVmax<8风险增加5.48倍。
  • 中位随访19.5个月(范围0.4-48个月)时,74.6%(53/71)患者无进展。

核心结论

  • 腺内68Ga-PSMA-11强度具有预后价值,可能成为局限性前列腺癌的新生物标志物,尤其适用于活检证实Gleason 3+4且考虑初始主动监测或局灶治疗的患者。

研究设计与样本

  • 队列研究,纳入71例经MRI引导活检证实前列腺癌并在根治性前列腺切除术前接受68Ga-PSMA-11 PET/CT的患者。
  • 采用多变量统计分析,评估腺内PSMA强度与不良病理结局(Gleason评分、活检升级、病理分期)及无进展生存期的相关性。

主要发现

  • 68Ga-PSMA-11 PET/CT体内强度可预测根治性前列腺切除术后Gleason评分、活检至根治性前列腺切除病理升级、病理分期、切缘阳性和无进展生存期。
  • 中位随访19.5个月(范围0.4-48个月)时,74.6%(53/71)患者无进展。
  • 活检Gleason评分≤3+4患者(n=39)中,PSMA强度是無进展生存期最显著预测因子;Cox回归校正生存分析显示,高PSMA强度(SUVmax>8)较低PSMA强度(SUVmax<8)风险增加5.48倍。

关键数值与推荐

  • 高PSMA强度定义为SUVmax>8,低PSMA强度定义为SUVmax<8。
  • 活检Gleason评分≤3+4患者中,高PSMA强度(SUVmax>8)较低PSMA强度(SUVmax<8)的进展风险增加5.48倍。

临床怎么用

  • 腺内68Ga-PSMA-11强度可能成为局限性前列腺癌的新生物标志物,尤其适用于活检证实Gleason 3+4且考虑初始主动监测或局灶治疗的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate-specific membrane antigen (PSMA) positron emission tomography (PSMA-PET) improves prostate cancer staging. Intraprostatic PSMA intensity may predict clinically relevant oncological outcomes. The aim of this study was to investigate the relationship between intraprostatic PSMA intensity and adverse pathology outcomes, including biochemical progression-free survival (PFS) after radical prostatectomy. METHODS: This is a cohort study of 71 patients with MRI-guided, biopsy-proven prostate cancer and pre-operative 68Ga-PSMA-11 PET/CT prior to radical prostatectomy (RP). Intraprostatic PSMA intensity was correlated to adverse pathology outcomes (Gleason score and upgrading from biopsy, pathological stage) and PFS using multivariate statistical analysis. RESULTS: 68Ga-PSMA-11 PET/CT intensity in vivo predicted all of Gleason score on RP, upgrading from biopsy to RP histopathology, pathological stage, positive surgical margins and PFS. 74.6% (53/71) of patients were free from progression at a median follow-up of 19.5 months (0.4-48 months). Predictive accuracy was particularly enhanced by PSMA among patients with biopsy Gleason score ≤ 3 + 4 (n = 39) as the most significant predictor of PFS according to Cox-proportional hazards regression. Cox-regression adjusted survival analysis predicted a 5.48-fold increase in hazard for Gleason score ≤ 3 + 4 patients with high (SUVmax > 8) compared with low (SUVmax < 8) PSMA intensity. CONCLUSION: Intraprostatic 68Ga-PSMA-11 intensity is prognostic and may be a valuable new biomarker in localised prostate cancer, especially in men with biopsy-proven Gleason 3 + 4 disease considering an initial approach of active surveillance or focal therapy.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Roberts MJ, Morton A, Donato P, et al. 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer. Eur J Nucl Med Mol Imaging. 2020. PMID: 32696091. doi:10.1007/s00259-020-04944-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。